Community stories and news

We are thrilled to announce that ProQR has achieved the Great Place To Work (GPTW) certification following the results of an independent employee survey from GPTW Netherlands.

As a mission-driven company dedicated to changing lives by developing RNA therapies for severe rare and common diseases. ProQR recognizes the importance of advancing diversity, equity, and inclusivity (DEI) in the workplace to inspire each employee to fully thrive and to make their maximum contribution to ProQR.

Throughout the year ProQR regularly welcomes student groups from across the Netherlands.

In this personal interview, we speak to ProQR’s Chief Corporate Development Officer & General Counsel, René Beukema on his return to ProQR.

Partnerships in our industry are very common as companies look to benefit from knowledge and resource sharing. In this blog we explore why companies, like ProQR, partner with other companies.

In September 2021 ProQR announced a global licensing and research collaboration with Lilly. The partnership focuses on developing potential medicines using our Axiomer RNA editing platform technology. Strategic collaborations like this can help to drive the advancement of an early-stage technology, like Axiomer, closer to the clinic.

This month several ProQRians will attend the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022 to highlight our Axiomer® RNA-editing platform technology.

Announced today (August 11, 2022), ProQR will focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple therapeutic areas. This comes following feedback from the European Medicines Agency (EMA) related to ProQR’s sepofarsen for Leber Congenital Amaurosis type 10 (LCA10).

At ProQR we strive to create an inclusive culture where everyone is valued for who they are and individual differences and contributions are recognized and appreciated. Therefore, we decided for this Pride Month June 2022, to visually demonstrate our support and acknowledgment of the LGBTQ+ community by changing our logo to incorporate the pride rainbow flag.

ProQR has announced the completion of an in-depth strategic review designed to deliver on our commitment to advance RNA therapies for diseases with high unmet need. We are also sharing additional analyses of the sepofarsen Illuminate trial.

On behalf of all ProQRians, happy Rare Disease Day 2022. Both within ProQR and outside, we join the community in raising awareness and trying to generate change for people worldwide living with a rare disease, their families, and supporters.

In top-line analyses, the Illuminate study did not meet its primary endpoint of Best Corrected Visual Acuity (BCVA) and secondary endpoints. No benefit was observed in either sepofarsen treatment arm versus the sham treated control arm.